In sum, current evidence positions GLP-1 RAs as a potential cardioprotective strategy in HF, with HF with preserved ejection fraction emerging as the clinically most relevant phenotype for the drug class, especially when occurring in people with obesity with and without diabetes. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.